Alimera Sciences Inc (NASDAQ: ALIM), a biopharmaceutical company stock, is our featured top momentum gainer of the day. The stock gained over 8% in the last two trading sessions and registered a new intraday 52-week high with far more shares changing hands than in a normal session. During the last trading session, ALIM was among the top gainers in the U.S. healthcare sector, rising 19% and closed at a 52-week high of $7.19 while recording volumes of 1.10 million shares. During the past 5-trading sessions, the stock gained 58.3% with average volumes of 593,472 shares. A new uptrend in share prices was witnessed after ALIM accumulated over 183% in the past one month with daily average volume of 410,338 shares. Recently, ALIM reported it has started shipping the initial orders of its ILUVIEN product to several U.K. National Health Service (NHS) facilities. On January 10, 2014, the first NHS patient received an ILUVIEN implant for the treatment of chronic diabetic macular edema (DME).
Company Description:
Alimera Sciences Inc (NASDAQ: ALIM) is a biopharmaceutical company which researches, develops and commercializes prescription ophthalmic pharmaceuticals. Alimera Sciences is focused on diseases affecting the lining in the back of the eye, or retina.
1-Year Stock Chart:
Source: Bloomberg
